Skip to main content
Andrew Kwok on Muck Rack

Andrew Kwok

New York, Newport Beach
As seen in: Commercial Observer, Nature, SAGE Publishing, Taylor & Francis Online, Education Week, BioRxiv, Cell Metabolism, EdSurge, medRxiv, EdSource, Kappan
CRE Finance and Investment | Principal of Arcus Harbor Real Estate Capital
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andrew

Contact Andrew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Body-wide multi-omic counteraction of aging with GLP-1R agonism

|
By Junzhe Huang, Andrew Kwok, Bonaventure Ip, Lok Yi Tung, Roy Chan, Danny Chan, Ziyu Wang, Xianyi Zheng, Michelle Lo, Zhongqi Li, Nenghan Lin, Manyu Wang, Leo Yan, William Wu, Kim Hei-Man Chow, Wei-Jye Lin, Yamei Tang, Yun Zhang, Weihong Song, Billy Wai-Lung Ng, Thomas W. Leung, Vincent C.T. Mok, Ho Ko
| Cell Metabolism Verified
Main text (Cell Metabolism 37, 2362–2380.e1–e8; December 2, 2025) Following publication, Steve Horvath and colleagues at the Clock Foundation alerted us to a platemap error in the DNA methylation (DNAm) data. Our investigation pinpointed the potential source of this error. We provided samples on 96-well plates in a row-wise orientation instead of the column-wise orientation specified in the Clock Foundation’s protocol.
Open in Who Shared Issue with article?

Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy—a phase 2 randomized trial - Nature Communications

|
By Ho Ko, Andrew Kwok, Anne Chan, Ho Sang Leung, Jill Abrigo, Xinyi Leng, Thanh Nguyen
| Nature Verified
Abstract We aimed to determine the effect of semaglutide on patients with acute large vessel occlusion (LVO) receiving endovascular therapy (EVT). In this phase 2, investigator-initiated, multicenter, prospective, randomized, open-label, blinded endpoint trial conducted in China, we recruited patients with disabling LVO undergoing EVT. Patients were randomized to semaglutide therapy (0.5 mg subcutaneous semaglutide before and 1 week after EVT) or standard therapy.
Open in Who Shared Issue with article?

Body-wide multi-omic counteraction of aging with GLP-1R agonism

|
By Junzhe Huang, Andrew Kwok, Bonaventure Ip, Lok Yi Tung, Roy Chan, Danny Chan, Ziyu Wang, Xianyi Zheng, Michelle Lo, Zhongqi Li, Manyu Wang, Leo Yan, William Wu, Kim Hei-Man Chow, Wei-Jye Lin, Yamei Tang, Yun Zhang, Weihong Song, Billy Wai-Lung Ng, Thomas W. Leung, Vincent C.T. Mok, Ho Ko, Nenghan Lin
| Cell Metabolism Verified
Keywords aging GLP-1R agonist multi-omics mTOR inhibition brain-body interaction exenatide rapamycin Introduction Aging is a complex process involving diverse cellular and molecular alterations across all body systems, resulting in progressive functional decline. Discovering effective strategies to counteract aging-associated changes is a significant scientific pursuit with profound societal implications, given the potential to improve overall well-being and extend healthy lifespan.
Open in Who Shared Issue with article?
See all 22 articles